Humana (HUM) to Release Quarterly Earnings on Tuesday

Humana (NYSE:HUM) is projected to announce its earnings results before the market opens on Tuesday, February 11th. Analysts expect the company to announce earnings of ($2.26) per share and revenue of $28.84 billion for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Humana Stock Down 0.1 %

Shares of NYSE:HUM opened at $292.82 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The company has a market capitalization of $35.26 billion, a PE ratio of 25.94, a P/E/G ratio of 2.21 and a beta of 0.56. Humana has a 52 week low of $213.31 and a 52 week high of $406.46. The company’s fifty day moving average is $275.36 and its 200-day moving average is $301.04.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on HUM. Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Stephens reiterated an “equal weight” rating and set a $250.00 price target on shares of Humana in a research report on Wednesday, October 9th. Wells Fargo & Company lowered their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. TD Cowen upped their target price on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Finally, Royal Bank of Canada reduced their price objective on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $297.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.